Kosovec, J., Rotoloni, C., Zaidi, A. H., Komastu, Y., Kelly, L., Matsui, D., … Jobe, B. A. (2014). Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal adenocarcinoma. In Journal of Clinical Oncology (Vol. 32, pp. e13506–e13506). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.e13506

Kosovec, Juliann, Christina Rotoloni, Ali H. Zaidi, Yoshihiro Komastu, Lori Kelly, Daisuke Matsui, Amina Waheed, Toshitaka Hoppo, and Blair A. Jobe. “Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal adenocarcinoma.” In Journal of Clinical Oncology, 32:e13506–e13506. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e13506.

Kosovec J, Rotoloni C, Zaidi AH, Komastu Y, Kelly L, Matsui D, et al. Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal adenocarcinoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. e13506–e13506.

Kosovec, Juliann, et al. “Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal adenocarcinoma.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. e13506–e13506. Crossref, doi:10.1200/jco.2014.32.15_suppl.e13506.

Kosovec J, Rotoloni C, Zaidi AH, Komastu Y, Kelly L, Matsui D, Waheed A, Hoppo T, Jobe BA. Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal adenocarcinoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. e13506–e13506.